GlassScriptPhysician profile
Roxann Rodriguez
NPI 1710327622
$1,492.26
in general payments reported to CMS, 2019-2025
22 companies · $24.35 in 2025
The $24.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.33 · 2022: $368 · 2023: $625 · 2024: $410 · 2025: $24.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $222.61 | 2022-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $169.05 | 2021-2025 | Wegovy |
| Exact Sciences Corporation | $165.93 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $160.12 | 2022-2024 | |
| Abbvie INC. | $134.19 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.59 | 2022-2023 | |
| Lilly USA, LLC | $103.55 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $100.18 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $64.21 | 2021-2022 | |
| Amgen INC. | $46.60 | 2023-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $33.46 | 2023 | Wavewriter Alpha Prime 16, Watchman Access System |
| Lucid Diagnostics INC. | $19.47 | 2023 | |
| Merck Sharp & Dohme LLC | $19.34 | 2022 | |
| Medtronic, INC. | $18.47 | 2024 | Intellis Adaptivestim |
| Mannkind Corporation | $18.46 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.42 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $16.51 | 2024 | Voquezna |
| Astellas Pharma US INC | $15.60 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Currax Pharmaceuticals LLC | $12.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxann Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.